# Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval: Draft Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/minimal-residual-disease-and-complete-response-in-multiple-myeloma-use-as-endpoints-to-support-accelerated-approval-draft-guidance-for-industry/06f37c31-445c-4690-8220-150703bde2bd

> FDA guidance document: Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval: Draft Guidance for Industry. Issue date: January 21, 2026. Get complete insights and analysis.

---

## Details

- Title: Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: other
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2026-01-21
- Last Changed: 2026-01-20
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2025-D-2616">FDA-2025-D-2616</a>

## Related Documents

- [Master Protocols for Drug and Biological Product Development](https://www.globalkeysolutions.net/guidances/guidance-document/master-protocols-for-drug-and-biological-product-development/401e65ec-7388-4389-a95a-dc8860a1ce51)
- [Labeling for Biosimilar and Interchangeable Biosimilar Products](https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-biosimilar-and-interchangeable-biosimilar-products/54a5f712-03f5-4993-b0d7-6a1c2f261eff)
- [Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-trial-considerations-to-support-accelerated-approval-of-oncology-therapeutics/adf9cb72-5955-4d5f-8f26-4e226281ace9)